FDA Accepts Supplement Application for Depemokimab by GlaxoSmithKline
The FDA has accepted the supplemental application for BLA761458, a biologic from GlaxoSmithKline.
Asset / Drug
Drug and asset intelligence for Depemokimab with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.